Maria Rowena Del Rosario‐Raymundo

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials

Aimée R. Kreimer, Frank Struyf, Maria Rowena Del Rosario‐Raymundo et al. · The Lancet Oncology · 2015 · 298 citations · Full text

Vaccination, Hpv-16/18 As04-adjuvanted Vaccine, Costa Rica Vaccine +10

Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study

Unnop Jaisamrarn, Xavier Castellsagué, Suzanne M. Garland et al. · PLoS ONE · 2013 · 206 citations · Full text

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Cosette M. Wheeler, S. Rachel Skinner, Maria Rowena Del Rosario‐Raymundo et al. · The Lancet Infectious Diseases · 2016 · 187 citations

Vaccination, Vaccine Safety, Vaccinology +12

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

S. Rachel Skinner, Anne Szarewski, Barbara Romanowski et al. · The Lancet · 2014 · 180 citations

Vaccination, Vaccine Safety, Vaccinology +13

Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study

S. Rachel Skinner, Cosette M. Wheeler, Barbara Romanowski et al. · International Journal of Cancer · 2015 · 114 citations · Full text